Abstract
We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).
Original language | English |
---|---|
Pages (from-to) | 289-295 |
Number of pages | 7 |
Journal | Bone |
Volume | 50 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2012 |
Bibliographical note
Bone Volume 50, Issue 3, March 2012, Page 811Corrigendum to “Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate” [Bone 50 (2012) 289-295] https://doi.org/10.1016/j.bone.2011.12.006